Halozyme Therapeutics Sees FY24 Adj. EPS $4.00-$4.20 To $3.96 Est.; Revenue $970M-$1.020B Vs $983.852M Est.
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics has provided its financial guidance for FY24, projecting adjusted EPS between $4.00 and $4.20, slightly above the consensus estimate of $3.96. The company also expects revenue to range from $970 million to $1.020 billion, compared to the estimated $983.852 million.
October 31, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has issued FY24 guidance with adjusted EPS expected to be higher than consensus estimates, and revenue projections slightly varying around the estimate.
The guidance provided by Halozyme Therapeutics indicates a positive outlook with adjusted EPS expected to exceed market expectations. Revenue projections are close to estimates, suggesting stable financial performance. This positive guidance is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100